Mipsagargin

DB11813InvestigationalSmall molecule

Mipsagargin has been used in trials studying the treatment of Prostate Cancer, Prostatic Neoplasms, Advanced Solid Tumors, Glioblastoma Multiforme, and Hepatocellular Carcinoma, among others.

Formula / weight: C₆₆H₁₀₀N₆O₂₇ · 1409.541 g/mol (avg)
Code names: G-202

Resolves to

Compound

UNIIQ032I35QMXCAS1245732-48-2ChEMBLCHEMBL3989865PubChem24772106

Structure

InChIKeyUPYNTAIBQVNPIH-ODMLWHIESA-NSMILES

CCCCCCCC(=O)O[C@@H]1[C@@H](OC(=O)C(\C)=C/C)C(C)=C2[C@@H]3OC(=O)[C@@](C)(O)[C@@]3(O)[C@H](C[C@](C)(OC(C)=O)[C@@H]12)OC(=O)CCCCCCCCCCCNC(=O)C[C@H](N)C(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(=O)N[C@@H](CCC(O)=O)C(O)=O)C(O)=O)C(O)=O)C(O)=O

Targets

Q04609FOLH1

What you can answer from here — as of January 29, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

8Clinical trialsPhase, status and sponsor resolved per trial

1+ReferenceStructured and connected to the statements they support

Which drugs share a target with Mipsagargin, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account